Multiple myeloma is a globally distributed haematological cancer, and Lenalidomide (Revlimid) has transformed outcomes for myeloma patients worldwide. Unnati Pharmax supplies generic Lenalid 25mg to patients and oncology clinics across the Philippines, South Africa, Australia, and Singapore — making this essential IMiD therapy accessible at a fraction of brand Revlimid's cost.
In the Philippines, myeloma patients in Manila, Cebu, and Davao face brand Revlimid costs exceeding PHP 400,000 monthly — completely unaffordable for the vast majority. Generic Lenalid from Unnati Pharmax reduces this to a manageable level for private oncology clinic patients. In South Africa, the private oncology sector at Netcare, Mediclinic, and Life Healthcare hospitals serves myeloma patients whose medical aids face rapidly escalating oncology costs — generic Lenalid offers significant formulary cost savings. In Sydney, Melbourne, Brisbane, and Singapore, self-funding patients and those with partial insurance coverage benefit from generic access at dramatically lower out-of-pocket cost.
All Lenalid shipments include full WHO-GMP certificates, certificates of analysis, and country-specific documentation. Visit medshopy.com or WhatsApp +91 82650 41513.
❓ Is multiple myeloma more common in some populations than others, and why?
Yes — multiple myeloma shows significant variation in incidence across populations. Black/African-descent populations have approximately twice the myeloma incidence rate of white populations globally — one of the most striking racial disparities in oncology. The reasons are not fully understood but likely involve a combination of genetic predisposition (specific immunoglobulin gene variants), higher rates of MGUS (monoclonal gammopathy of undetermined significance, the precursor condition) in Black populations, and possibly environmental factors. In contrast, Asian populations generally have lower myeloma incidence rates. South Africa's diverse population — with its large Black African majority — thus carries a significant myeloma burden, making affordable Lenalid access particularly impactful there. Philippines, Singapore, and Australia's Asian-majority communities have relatively lower but still clinically significant myeloma incidence requiring treatment access solutions.